Engineering of GlcNAc-1-Phosphotransferase for Production of Highly Phosphorylated Lysosomal Enzymes for Enzyme Replacement Therapy

Research output: Contribution to journalArticle

7 Scopus citations

Abstract

Several lysosomal enzymes currently used for enzyme replacement therapy in patients with lysosomal storage diseases contain very low levels of mannose 6-phosphate, limiting their uptake via mannose 6-phosphate receptors on the surface of the deficient cells. These enzymes are produced at high levels by mammalian cells and depend on endogenous GlcNAc-1-phosphotransferase α/β precursor to phosphorylate the mannose residues on their glycan chains. We show that co-expression of an engineered truncated GlcNAc-1-phosphotransferase α/β precursor and the lysosomal enzyme of interest in the producing cells resulted in markedly increased phosphorylation and cellular uptake of the secreted lysosomal enzyme. This method also results in the production of highly phosphorylated acid β-glucocerebrosidase, a lysosomal enzyme that normally has just trace amounts of this modification.

Original languageEnglish
Pages (from-to)59-65
Number of pages7
JournalMolecular Therapy - Methods and Clinical Development
Volume5
DOIs
StatePublished - Jun 16 2017

Keywords

  • GlcNAc-1-phosphotransferase
  • enzyme replacement therapy
  • lysosomal enzyme
  • lysosomal storage disorders
  • mannose 6-phosphate

Fingerprint Dive into the research topics of 'Engineering of GlcNAc-1-Phosphotransferase for Production of Highly Phosphorylated Lysosomal Enzymes for Enzyme Replacement Therapy'. Together they form a unique fingerprint.

  • Cite this